Two posters with POLB 001 preclinical data presented at the European Hematology Association Congress
RNS Hotlist with Zak Mir: KEN, WSBN, EPP, AAU, MDH, KZG, GDR, BHL, FORG, GGP, EARN, PALM, POLB & BSFA
Kendrick Resources Plc (KEN), the mineral exploration and development company, announced a fundraising of £1,764,000 from Directors, a U.S. managed fund, a U.S. family office and existing shareholders.
Poolbeg Pharma (AIM: POLB) Pre-IND Meeting with the FDA for POLB 001
FDA feedback supports Poolbeg’s proposed development pathway for POLB 001, providing further clarity for ongoing partnering discussions
POLB 001 poster to be presented at EHA 2026 Congress
Poolbeg Pharma plc is set to present new data on its drug candidate POLB 001 at the upcoming European Hematology Association Congress 2026, highlighting the treatment’s potential to prevent cancer
RNS Hotlist with Zak Mir: ABDX, CLBX, POLB, 88E, GAL, ROCK, EEE, PALM, NTVO, DGQ, HAMA, HODL, KEN & 80M
Abingdon Health plc (ABDX), a leading international developer, manufacturer and regulatory services provider for rapid diagnostic tests and med-tech, noted the announcement on 5 May 2026 by its customer, UpFront Diagnostics,
POLB 001 cancer immunotherapy-induced CRS patent granted in Canada
Further strengthening of Poolbeg’s global intellectual property portfolio
Share Talk Weekly Stock Market News Review, Sunday 10th May 2026
Britain’s FTSE 100 recorded its third consecutive weekly decline after closing 43 points lower, down 0.4%, at 10,233.07 on Friday. The more domestically focused FTSE 250 also ended weaker, slipping 0.15% to close
Why 2026 could be a defining year for Poolbeg Pharma
Poolbeg Pharma (AIM: POLB) enters 2026 at a point where several years of methodical clinical and strategic groundwork are beginning to converge. After a deliberately measured 2025 focused on trial
Poolbeg Pharma is stepping up partnering discussions with multiple pharma groups
Poolbeg Pharma PLC (AIM: POLB) is stepping up partnering discussions with multiple pharma groups as it approaches a series of near-term clinical catalysts that could unlock a deal.
Poolbeg Pharma CEO speaks on BioHub podcast in London
In this episode of The BioHub Podcast, Max sits down in person in London with Jeremy Skillington, CEO of Poolbeg Pharma.
Share Talk Weekly Stock Market News Review, Sunday 19th April 2026
The AIM All-Share Index extended its rebound with another solid week, climbing 2.7%. The benchmark once again outperformed the FTSE 100, which finished the week broadly flat.
Why 2026 could be a defining year for Poolbeg Pharma
Poolbeg Pharma (AIM: POLB) enters 2026 at a point where several years of methodical clinical and strategic groundwork are beginning to converge. After a deliberately measured 2025 focused on trial